Please assess the completion status of the following clinical trial:

Trial Title: Temsirolimus and Bevacizumab in Treating Patients With Stage III or Stage IV Malignant Melanoma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Histologically or cytologically confirmed melanoma~  * Stage III or IV disease~    * Recurrent disease allowed~* Measurable disease defined as ≥ 1 lesion that can be accurately measured in ≥ 1 dimension as ≥ 20 mm with conventional techniques OR ≥ 10 mm with spiral CT scan~  * Tumor lesions in previously irradiated areas are not considered measurable disease~* Prior brain metastases allowed provided all of the following criteria are met:~  * No more than a total of 5 brain metastases~ * All metastases are no more than 2.5 cm~ * Surgically resected or have been treated with gamma-knife or stereotactic radiosurgery~ * More than 30 days since prior disease progression~ * More than 30 days since prior steroids for managing brain metastases~    * Concurrent steroids for other reasons allowed provided the dose is \< that required for managing brain metastases~* Disease accessible for core needle biopsy, incisional biopsy, and/or surgical resection and meets one of the following criteria:~  * One large tumor deposit ≥ 5 cm³ from which biopsies can be harvested multiple times~ * Multiple deposits that can be biopsied or excised individually on different dates, measured as follows:~    * One lesion ≥ 5 cm\^3~   * Two lesions ≥ 3 cm\^3~   * Three lesions ≥ 2 cm\^3~* ECOG performance status 0-1~* Weight ≥ 110 pounds (without clothes)~* WBC ≥ 3,000 mm³~* Absolute neutrophil count ≥ 1,500/mm³~* Platelet count ≥ 100,000/mm³~* Bilirubin normal~* AST and ALT ≤ 2.5 times upper limit of normal~* Creatinine normal OR creatinine clearance ≥ 60 mL/min~* Urine protein: creatinine ratio \< 1.0 OR 24-hour urine protein \< 1,000 mg~* Fasting cholesterol \< 350 mg/dL (cholesterol medications are allowed)~* Fasting triglycerides \< 400 mg/dL~* PT INR ≤ 1.5 (unless on full-dose anticoagulants)~* Hematocrit \< 41% (for males) or \< 38% (for females)~* None of the following within the past 4 weeks:~  * Uncontrolled intercurrent illness~ * Ongoing or active acute (CTCAE v.3 grade 3 or 4) infection~ * Abdominal fistula~ * Gastrointestinal perforation~ * Intra-abdominal abscess~ * Serious or nonhealing wound, ulcer, or bone fracture~* No psychiatric illness or social situations that would preclude study compliance~* No clinically significant cardiovascular disease, including the following:~  * Cerebrovascular accident within the past 6 months~ * Transient ischemic attack within the past 6 months~ * Myocardial ischemia within the past 6 months~ * Myocardial infarction within the past 6 months~ * Other thromboembolic event within the past 6 months~ * Unstable angina within the past 6 months~ * Uncontrolled hypertension (i.e., hypertension despite maximal therapy)~ * New York Heart Association class II-IV heart disease~ * Congestive heart failure~ * Serious cardiac arrhythmia requiring medication~ * Clinically significant peripheral vascular disease~ * History of stroke~ * Artificial valve, pacemaker, or similar device~* No uncontrolled diabetes~  * Hemoglobin A1c \< 7%~* No significant traumatic injury within the past 28 days~* No history of allergic reactions to compounds of similar chemical or biological composition to temsirolimus or bevacizumab~* No hypersensitivity to Chinese hamster ovary cell products or other recombinant human antibodies (e.g., infliximab)~* Not pregnant or nursing~* Negative pregnancy test~* Fertile patients must use effective contraception during and for ≥ 6 months after completion of study treatment~* HIV negative~* Hepatitis C negative~* See Disease Characteristics~* More than 4 weeks since any of the following prior treatments and recovered:~  * Chemotherapy (6 weeks for nitrosoureas or mitomycin C)~ * Radiotherapy to nontarget lesions or lesions that are not to be biopsied~ * Immunotherapy~ * Cytokine therapy~ * Enzyme-inducing antiepileptic drugs (EIAEDs) or other CYP3A4 inducers~ * Investigational agents~* More than 4 weeks since prior major surgery or open biopsy and recovered~* No prior temsirolimus, rapamycin, bevacizumab, or systemic therapies targeted primarily to vascular endothelial growth factor (VEGF), VEGF receptors, or to mTOR inhibition~* Concurrent full-dose anticoagulants (e.g., warfarin/low molecular weight heparin) with PT INR \> 1.5 are allowed provided the following criteria are met:~  * In-range INR (usually between 2 and 3.5) on a stable dose of oral anticoagulant or on a stable dose of low molecular weight heparin~ * No active, clinically significant bleeding or pathological condition that carries a high risk of bleeding (e.g., tumor involving major vessels or known varices)~    * Minimal tumor bleeding of the skin allowed at the clinician's discretion~* No concurrent medications or substances known to affect or with the potential to affect the activity or pharmacokinetics of the following:~  * Temsirolimus~ * Bevacizumab~ * CYP450 isoenzymes~* No concurrent nonstudy-related surgical procedures~* No other concurrent anticancer agents or therapies~Exclusion Criteria~* Participants who have received these medications or treatments at any time ≤ 4 weeks of registration:~  * Chemotherapy~ * Radiotherapy to non-target lesions and lesions that are not to be biopsied. Prior radiotherapy to target lesions or lesions to be biopsied/resected is not permitted~ * Immunotherapy~ * Cytokine therapy~ * Investigational reagents~ * Invasive procedures defined as follows:~    * Major surgical procedure, open biopsy or significant traumatic injury~   * Anticipation of need for non-study related surgical procedures from registration until Cycle 26 (One year).~ * Enzyme-inducing antiepileptic drugs (EIAEDs) or any other CYP3A4 inducer (Appendix C).~OR Participants who have not recovered from adverse events resulting from the administration of these agents/procedures \> 4 weeks prior to registration.~* Participants who have received nitrosureas or mitomycin C ≤ 6 weeks of registration.~* History of allergic reactions attributed to compounds of similar chemical or biologic composition to CCI-779 or bevacizumab, or with known hypersensitivity to Chinese hamster ovary cell products (t-PA) or other recombinant human antibodies (e.g., Remicade®).~* Participants who have previously received CCI-779, rapamycin, bevacizumab, or systemic therapies targeted primarily to VEGF, VEGF receptors, or to mTOR inhibition.~* Participants who have experienced any of the following ≤ 4 weeks prior to registration:~  * Uncontrolled intercurrent illness~ * Infection, CTCAE3 grade 3 or 4 (either ongoing, chronic, or active infection)~ * Abdominal fistula~ * Gastrointestinal perforation~ * Intra-abdominal abscess~ * Serious or non-healing wound~ * Serious or non-healing ulcer~ * Serious or non-healing bone fracture.~* Potential subjects with clinically significant cardiovascular disease~  * Recent history (defined as ≤ 6 months of registration) of thromboembolic events including cerebrovascular accident (CVA), transient ischemic attack (TIA), myocardial ischemia, myocardial infarction (MI)~ * Uncontrolled hypertension (hypertension despite maximal therapy)~ * Unstable angina ≤ 6 months of registration~ * New York Heart Association Classification of ≥ class II heart disease~ * Congestive heart failure~ * Serious cardiac arrhythmia requiring medication~ * Clinically significant peripheral vascular disease~ * Have a history of stroke~ * Have an artificial valve, pace-maker, or similar device~* Psychiatric illness/social situations that would limit compliance with study requirements.~* Pregnant (positive pregnancy test) or nursing women. Both fertile men and women must agree to use adequate contraceptive measures during study therapy and for at least 6 months after the completion of their participation in the study therapy.~* PT INR \> 1.5, (unless the potential subject is on full dose anticoagulants and meet criteria described in Section 3.1.8).~* Participants with uncontrolled diabetes, defined as having a HGBA1C ≥ 7%.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Treatment (enzyme inhibitor, monoclonal antibody) (Type: EXPERIMENTAL): Patients receive temsirolimus IV over 30 minutes on days 1 and 8 and bevacizumab IV over 30-90 minutes on day 8. Treatment repeats every 14 days for a maximum of 26 courses in the absence of disease progression or unacceptable toxicity. Patients undergo tumor resection on day 9 of course 2.

Based on this trial design, predict the completion outcome and termination type (if applicable).